We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Functional MRI (fMRI) Offers Non-Invasive Method for Risk Assessment in Liver Disease

By HospiMedica International staff writers
Posted on 20 May 2022

In a recent study, a team of scientists has shown that functional magnetic resonance imaging (fMRI) can be used as a non-invasive method for predicting complications in chronic liver disease. More...

The scientists combined a simple risk stratification system developed at Medical University of Vienna (Vienna, Austria) - the functional liver imaging score (FLIS) - with splenic diameter. This new non-invasive method can be used to complement invasive investigations. For their study, the multidisciplinary group of researchers analyzed patients with liver cirrhosis. The FLIS was confirmed to be extremely useful as a supplement to and/or replacement for existing invasive procedures for estimating severity and mortality risk. In the recent study, the scientists combined FLIS and splenic diameter for the first time to refine the new non-invasive method. This combination provided them with complementary data for risk assessment in patients with advanced chronic liver disease.

FLIS was assessed by fMRI using a liver-specific contrast agent and is plotted on a scale of 0 to 6 points. The study found that patients with advanced liver disease and a low FLIS (0-3 points) or a high FLIS (4-6 points) but a large spleen (>13cm diameter) had a 3.2-fold increased risk of liver-associated complications compared with patients with a high FLIS (4-6 points) and small spleen (≤13cm). Furthermore, irrespective of spleen size, patients with a low FLIS (0-3 points) had an 8.5-fold increased risk of death compared with those with a high FLIS (4-6 points) and small spleen (≤13cm).

With the combination of FLIS and spleen size, the researchers addressed the fact, long known in medicine, that patients with chronic liver disease often have high blood pressure in the circulatory system upstream of the liver (portal hypertension). This promotes the development of complications and leads to enlargement of the spleen: the more severe the liver disease, the more pronounced the portal hypertension - and the larger the spleen. The findings from the study will now be confirmed by multicentre clinical trials, i.e. clinical trials conducted in parallel at different institutions.

Related Links:
Medical University of Vienna 


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Multi-Chamber Washer-Disinfector
WD 390
Creatinine/eGFR Meter
StatSensor® Creatinine/eGFR Meter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.